Fresh­ly baked: Pret­zel Ther­a­peu­tics takes out the oven mitts to drug dis­eases in the pow­er­house of the cell 

Af­ter help­ing co-found Vir Biotech­nol­o­gy and lead the biotech’s busi­ness de­vel­op­ment through the first few years, in­clud­ing a rare emer­gency use au­tho­riza­tion for a Covid-19 treat­ment, Jay Par­rish has found a new home at the pret­zel pow­er­house.

Fo­cused on the so-called pow­er­house of the cell, the mi­to­chon­dria, Pret­zel Ther­a­peu­tics emerged Mon­day with $72.5 mil­lion in Se­ries A back­ing from ARCH Ven­ture Part­ners and Mubadala Cap­i­tal, along with a syn­di­cate of oth­er in­vestors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER